[26H-pm] Radiopharmaceuticals-1

Sat. Mar 26, 2022 1:30 PM - 2:42 PM [Room H] Conference Room 221 (Bldg. 2: 2F)

Chair: Yasuhiko Iida

+Add all to schedule

1:30 PM - 1:42 PM

[26H-pm01S] Development of radioiodinated BODIPY-conjugated Hoechst for Auger Therapy

○Ryotaro Onoue¹, Hiroyuki Watanabe¹, Shimpei Iikuni¹, Masahiro Ono¹ (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)

1:42 PM - 1:54 PM

[26H-pm02S] Development of novel glucagon-like peptide-1 receptor-targeting probes modified with albumin binders for nuclear medicine diagnosis of insulinoma

○Takaki Ohara¹, Shimpei Iikuni¹, Hiroyuki Watanabe¹, Masahiro Ono¹ (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)

1:54 PM - 2:06 PM

[26H-pm03S] Synthesis and evaluation of a multifunctional probe introduced with tumor- and bone-targeting carrier in a molecule

○Saki Hirata¹, Takuma Higashi¹, Yuka Ando¹, Kenji Mishiro², Takeshi Fuchigami¹, Kazuhiro Shiba³, Seigo Kinuya¹, Kazuma Ogawa^1,2 (1. Grad. Sch. Med. Sci., Kanazawa Univ., 2. InFiniti., Kanazawa Univ., 3. Res. Ctr., Kanazawa Univ. )

2:06 PM - 2:18 PM

[26H-pm04S] Development of a radiogallium-labeled tumor imaging agent that recognizes negative charged region
and integrin on the surface of cancer cell membrane.

○Kohei Shimo¹, Takeshi Fuchigami¹, Kenji Mishiro², Kazuhiro Shiba³, Seigo Kinuya¹, Kazuma Ogawa^1,2 (1. Grad. Sch. Med. Sci., Kanazawa Univ., 2. InFiniti., Kanazawa Univ., 3. Dis. Mod., Kanazawa Univ.)

2:18 PM - 2:30 PM

[26H-pm05S] Synthesis and evaluation of novel granzyme B-targeting ¹¹¹In-labeled imaging probes for predicting the therapeutic efficacy of immune checkpoint inhibitor-based therapy

○Nobuki Kazuta¹, Shimpei Iikuni¹, Hiroyuki Watanabe¹, Masahiro Ono¹ (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)

2:30 PM - 2:42 PM

[26H-pm06S] Influence of immune checkpoint inhibitor on tumor hypoxia

○Mitsunori Homma¹, Kohei Nakajima², Motofumi Suzuki², Yuta Yokouchi², Takuma Matsuda¹, Hideo Takakura², Kenji Hirata^3,4, Yuji Kuge⁵, Mikako Ogawa² (1. Fac. Pharm. Sci., Hokkaido Univ., 2. Grad. Sch. Pharm. Sci., Hokkaido Univ., 3. Grad. Sch. Med., Hokkaido Univ., 4. Hokkaido Univ. Hosp., 5. Cen. Inst. Isotope Sci, Hokkaido Univ.)

Session information

[26H-pm] Radiopharmaceuticals-1

[26H-pm01S] Development of radioiodinated BODIPY-conjugated Hoechst for Auger Therapy

[26H-pm02S] Development of novel glucagon-like peptide-1 receptor-targeting probes modified with albumin binders for nuclear medicine diagnosis of insulinoma

[26H-pm03S] Synthesis and evaluation of a multifunctional probe introduced with tumor- and bone-targeting carrier in a molecule

[26H-pm04S] Development of a radiogallium-labeled tumor imaging agent that recognizes negative charged region
and integrin on the surface of cancer cell membrane.

[26H-pm05S] Synthesis and evaluation of novel granzyme B-targeting ¹¹¹In-labeled imaging probes for predicting the therapeutic efficacy of immune checkpoint inhibitor-based therapy

[26H-pm06S] Influence of immune checkpoint inhibitor on tumor hypoxia

Authentication

Session information

[26H-pm] Radiopharmaceuticals-1

[26H-pm01S] Development of radioiodinated BODIPY-conjugated Hoechst for Auger Therapy

[26H-pm02S] Development of novel glucagon-like peptide-1 receptor-targeting probes modified with albumin binders for nuclear medicine diagnosis of insulinoma

[26H-pm03S] Synthesis and evaluation of a multifunctional probe introduced with tumor- and bone-targeting carrier in a molecule

[26H-pm04S] Development of a radiogallium-labeled tumor imaging agent that recognizes negative charged regionand integrin on the surface of cancer cell membrane.

[26H-pm05S] Synthesis and evaluation of novel granzyme B-targeting 111In-labeled imaging probes for predicting the therapeutic efficacy of immune checkpoint inhibitor-based therapy

[26H-pm06S] Influence of immune checkpoint inhibitor on tumor hypoxia

Authentication

[26H-pm04S] Development of a radiogallium-labeled tumor imaging agent that recognizes negative charged region
and integrin on the surface of cancer cell membrane.

[26H-pm05S] Synthesis and evaluation of novel granzyme B-targeting ¹¹¹In-labeled imaging probes for predicting the therapeutic efficacy of immune checkpoint inhibitor-based therapy